Market overview / summary

According to the research report published by Polaris Market Research, the Global Myopia And Presbyopia Treatment Market Size Is Expected To Reach USD 30.66 Billion By 2030, at a CAGR of 7.6% during the forecast period.

Myopia and presbyopia remain two of the world’s most pervasive refractive health challenges, affecting children, working-age adults and ageing populations in distinct but overlapping ways. Advances in diagnostics, optics, pharmacology and minimally invasive procedures have broadened the therapeutic toolkit: clinicians can now choose from optical interventions (specialty contact lenses and spectacle designs), corneal and intraocular surgical options, and a growing pipeline of pharmacologic treatments aimed at slowing disease progression or temporarily restoring near vision. These parallel developments are reshaping clinical pathways and creating new opportunities for device manufacturers, pharmaceutical firms and eye-care providers to deliver tailored, outcome-focused solutions. Recent clinical literature highlights that combining behavioural interventions (time outdoors, reduced near work) with clinical treatments yields stronger control of myopia progression, while a host of non-surgical and surgical options is expanding presbyopia care beyond reading glasses.

Market landscape and technology snapshot

Therapeutic approaches for myopia emphasize control of axial elongation and slowing progression in children and adolescents. Proven modalities include low-dose atropine eye drops, orthokeratology (overnight corneal reshaping lenses), and multifocal/bifocal contact lenses or spectacle lenses designed to impose peripheral defocus. For presbyopia, the landscape spans pharmacologic topical therapies that provide temporary near-vision improvement, corneal inlays and on-label refractive procedures, as well as advanced intraocular lens (IOL) technologies used during cataract surgery to restore multifocality. Improvements in drug delivery, lens design, and combined-modality care (for example, dual-use of atropine with optical devices) are gaining research traction and clinical adoption. 

Key market growth drivers

1. Rising prevalence and earlier onset of myopia — Epidemiologic trends showing increased myopia incidence in younger age groups are driving demand for effective control strategies and long-term management programs. The clinical and social costs of high myopia (pathologic retinal changes, greater lifetime visual disability risk) are prompting earlier screening and intervention initiatives.

2. Advances in non-surgical pharmacotherapy for presbyopia — New topical agents and novel delivery mechanisms that can temporarily restore near vision without invasive surgery are attracting significant clinical interest and are moving through late-stage trials, creating potential for wide patient acceptance and easy clinic adoption once approved. Recent late-stage trial results underscore the commercial potential of these agents.

3. Improved optical and contact-lens technologies — The refinement of multifocal and dual-focus contact lens designs, orthokeratology materials and spectacle lens constructions is improving comfort, compliance and efficacy in myopia control and presbyopia correction, enabling broader uptake in both pediatric and adult populations..

4. Greater awareness, screening and policy initiatives — Public-health attention to vision screening in schools and workplace vision programs, together with guideline updates from ophthalmic societies, increases early detection and treatment rates, expanding the addressable patient base for myopia control and presbyopia care programs.

Market research methodology

1. Clinical literature review and guideline analysis — Systematic analysis of peer-reviewed studies, meta-analyses and clinical guidelines to identify evidence-based treatments, consensus on dosing/regimens (e.g., atropine concentrations), and long-term safety data.

2. Primary interviews with clinicians and payors — Direct conversations with pediatric ophthalmologists, optometrists, cataract surgeons and reimbursement specialists to understand clinical adoption barriers, patient preferences, and cost/coverage dynamics that affect product uptake.

3. Product and technology benchmarking — Comparative evaluation of contact lens materials and designs, pharmacologic formulations and delivery systems, and surgical/intraocular device performance using published trials and real-world evidence to rank clinical utility and ease of integration.

4. Regional adoption and access assessment — Mapping of screening programs, regulatory approval timelines, manufacturing and distribution footprints, and localized patient-behavior factors (for example, school screening programs, cultural attitudes toward contact lens wear) to forecast adoption pathways across regions.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/myopia-presbyopia-treatment-market 

Regional analysis

• Asia-Pacific: The region carries a disproportionate share of global myopia cases and has shown rapid adoption of myopia management programs, driven by school screening initiatives and growing parental awareness. Optical interventions (multifocal contact lenses, orthokeratology) and low-dose atropine regimens are widely used, and several local manufacturers and clinical networks support scale-up of these services.

• North America: Uptake trends are shaped by strong clinical research activity, growing commercial availability of presbyopic pharmacotherapies under trials, and integrated eye-care networks that rapidly implement new workflows. Consumer interest in minimally invasive presbyopia treatments and multifocal contact lens solutions is notable.

• Europe: Emphasis on evidence-based practice, multidisciplinary research collaborations and reimbursement considerations guide adoption. Europe’s aging population and established cataract surgery infrastructure also support growth in premium IOL adoption for presbyopia correction.

• Rest of World (Latin America, Middle East, Africa): Adoption is heterogeneous — metropolitan centers often mirror advanced-care patterns with access to specialty contact lenses and surgical options, while broader awareness campaigns and access initiatives are required for rural and lower-resource settings.

Key companies and ecosystem players

• AbbVie
• ALCON Inc.
• Alcon Vision LLC
• Bausch & Lomb Incorporated
• Bausch Health Companies Inc.
• Carl Zeiss AG
• Essilor Ltd.
• Hagg Striet UK
• Johnson & Johnson Vision
• Nidek Corporation
• Orasis Pharmaceuticals
• Regeneron Pharmaceuticals Inc.
• Sydnexis
• The Cooper Companies Inc.
• Topcon Corporation
• Zimmer Ophthalmic Systems AG.

Applications and end-user highlights

• Pediatric and adolescent care: School-based screening programs and pediatric optometry clinics are the primary points of intervention for myopia control—approaches focused on slowing progression to avoid high myopia later in life.

• Working-age adults: Multifocal contact lenses and spectacle solutions that reduce digital-eye strain and provide convenient near vision support are widely used by professionals and commuters.

• Older adults and presbyopes: The emergence of pharmacologic drops, corneal inlays and premium IOLs offers alternatives to spectacles and traditional refractive surgery, expanding choice and personalizing care based on lifestyle and risk tolerance.

Conclusion

The myopia and presbyopia treatment landscape is undergoing meaningful transformation driven by convergent advances in optics, pharmacology and public-health action. For myopia, a stronger emphasis on early detection and evidence-based control strategies offers a pathway to reduce the long-term burden of high myopia. For presbyopia, the arrival of efficacious pharmacologic options and refinements in minimally invasive procedures expand patient choice beyond spectacles. Success in this evolving market will depend on rigorous clinical validation, clinician and public education, and delivery models that balance innovation with accessibility. Stakeholders who prioritize integrated care approaches, robust post-market evidence generation and partnerships across the vision-care ecosystem will be best positioned to capture value and improve visual outcomes across age groups.

More Trending Latest Reports By Polaris Market Research:

Cloud Kitchen Market

Endoscopy Visualization Systems Market

Virtual Data Room Market

Alpaca Apparel and Accessories Market: A Sustainable Alternative to Wool and Synthetic Fibers

Endoscopy Visualization Systems Market

Patient Temperature Monitoring Market

Germany Aluminum Nitride Ceramic Heaters Market

RegTech Market Size Worth US$ 66.15 Billion Propelled by 21.3 % CAGR From 2024 to 2032 Report By PMR

polyurea market